Human Genome · Methylation Research
Genome methylation is one of the core components of epigenetic research. It involves dynamic changes in chemical modifications on DNA molecules without altering the DNA sequence itself. Methylation research not only helps us deeply understand fundamental biological issues such as gene expression regulation, disease pathogenesis, the interaction between environment and genetics, as well as individual development and aging, but also provides crucial theoretical support for the development of precision medicine. With continuous technological advancements, methylation research plays an increasingly important role in the fields of life sciences and medicine.
On the occasion of iGeneTech’s 11th anniversary, we are honored to announce that the company will invest tens of millions of RMB to officially launch the “Capture All” initiative. Currently, we have successfully developed:
· BisCap® Human CpG Island Panel (a human genome CpG island methylation panel),
· BisCap® Mouse CpG Island Panel (a mouse genome CpG island methylation panel),
· BisCap® Multi-Cancer Early Detection Panel (a cancer early screening panel).
Now, we look forward to collaborating with you. The next liquid chip for the methylome awaits your definition!
The features of the BisCap® CpG Galaxy Panel include:
a) Bimodal design for CpG sites on both positive and negative strands: The CpG Galaxy Panel adopts a bimodal design for CpG sites on positive and negative strands, comprehensively covering the CpG sites in the target region.
b) Wide coverage range: This Panel covers a 100.75 Mb human genome region, containing over 3 million CpG sites and including 98% of the CpG sites on the 935K chip.
c) Cancer early-screening markers: It supplementarily covers 12 methylation markers for the early screening of 8 types of cancers (gastric cancer, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, liver cancer, esophageal cancer, and ovarian cancer), which is helpful for the early detection and diagnosis of cancers.
d) Low DNA input requirement: Only ≥ 5 ng of DNA is needed to meet the experimental requirements.
e) Different from solid-phase chips, there is no need to have 8 samples to perform the test; a single sample can initiate the testing process.
Basic Performance of BisCap® CpG Galaxy Panel
The BisCap® CpG Galaxy Panel, combined with the BisCap® hybridization system, demonstrates:
· A Coverage Rate of 99.07% for target regions,
· A Flank Reads Capture Rate of 90.16%,
· And a Rmdup Target 20%X Rate of 97.75%.
Figure 1. 200 ng of G304 gDNA was fragmented by sonication, converted using the EpiTect Fast DNA Bisulfite Kit, and subjected to library construction with the IGT® Methyl Fast Library Prep Kit v2.0. The library was then captured by the BisCap® CpG Galaxy Panel and sequenced on a NovaSeq 6000 with PE150 strategy.
Performance Comparison of BisCap® CpG Galaxy Panel in Single Hybridization and 8-plex Hybridization
The BisCap® CpG Galaxy Panel, combined with the BisCap® hybridization system, shows no significant difference in basic quality control indicators between single hybridization and 8-plex hybridization.
Figure 2. 200 ng of NA12878 gDNA was fragmented by sonication, converted using the EpiTect Fast DNA Bisulfite Kit, and subjected to library construction with the IGT® Methyl Fast Library Prep Kit v2.0. The library was then captured by the BisCap® CpG Galaxy Panel and sequenced on a NovaSeq 6000 with PE150 strategy.
Technical Reproducibility of BisCap® CpG Galaxy Panel
Using 200 ng of cell line DNA for library construction, two technical replicates were performed, demonstrating a methylation level consistency of R=0.98 between replicates.
Figure 3. 200 ng of G304 gDNA was fragmented by sonication, converted using the EpiTect Fast DNA Bisulfite Kit, and subjected to library construction with the IGT® Methyl Fast Library Prep Kit v2.0. The library was then captured by the BisCap® CpG Galaxy Panel and sequenced on a NovaSeq 6000 with PE150 strategy.
Methylation Level Consistency Between BisCap® CpG Galaxy Panel and WGBS
Using 200 ng of cell line DNA for both WGBS and CpG Galaxy Panel experiments, consistency analysis was performed on overlapping CpG sites. The results show a consistency of R=0.95 between the CpG Galaxy Panel and WGBS.
Figure 4. 200 ng of NA12878 gDNA was fragmented by sonication, converted using the EpiTect Fast DNA Bisulfite Kit, and subjected to library construction with the IGT® Methyl Fast Library Prep Kit v2.0. The libraries were then processed for WGBS and captured by the BisCap® CpG Galaxy Panel respectively, followed by sequencing on a NovaSeq 6000 with PE150 strategy.
Applications of the BisCap® CpG Galaxy Panel
The BisCap® CpG Galaxy Panel, covering over 3 million CpG sites (including 98% of those on the 935K array), is an ideal tool for early cancer screening and CpG marker discovery. In the field of early cancer detection, companies like Grail have demonstrated the success of methylation panel-based capture technologies in multi-cancer early screening.
Molecular Subtyping of Tumors:
Leveraging methylation signatures, the panel enables molecular classification of tumors, providing critical insights for prognostic assessment and treatment stratification. For example, specific methylation patterns may correlate with tumor aggressiveness, recurrence risk, and treatment sensitivity. Analyzing these patterns helps clinicians predict patient outcomes more accurately and tailor personalized treatment plans, thereby improving therapeutic efficacy and patient quality of life.
Complex Diseases & Aging Research:
The panel’s utility extends to studying complex diseases (e.g., cardiovascular diseases, diabetes, neurodegenerative disorders) and the aging process, both of which involve epigenetic regulation and gene expression changes. By profiling methylation dynamics, researchers can uncover disease mechanisms and identify novel therapeutic targets.
Ordering Information
CN
